Elsevier would be delighted to work with the California Institute for Regenerative Medicine (CIRM) ina publishing venture that is mutually beneficial. This proposal encompasses a number of initiativesaimed at supporting CIRM in achieving its underlying goals of:Raising the priority and awareness of translational stem cell researchFostering collaborations between stem cell biologists, clinicians and engineersAcceleration of the field of translational stem cell researchIn addition, Elsevier understands from discussions with Dr. D. Gibbons that CIRM would like to see avery rapid implementation an
d that there should be ample space to publish ‘negative results’.
The Elsevier proposal offers the following options:a)
The launch of a new journal, with both an online and a print component.b)
An immediate collaboration/affiliation between CIRM and Elsevier’
Stem Cell Research
Elsevier is a publishing company with a wealth of experience and a bounty of resources. It is CIRM’s
ideal partner in achieving its publishing goals. This proposal gives extensive details on two publishingoptions. The first is directly aligned with the RFP and provides a path to a new journal launch. The
second, based on the proposal writers’ 40+ years of experience, offers a quicker, more efficient, and
more comprehensive alternative to achieving the same goals. Elsevier is uniquely position to makeeither of these options a reality. And further, Elsevier, based on its storied history of success, is theperfect long-term partner to carry out and adapt goals for the decades to come.